Pirfenidone stabilized the mitochondrial membrane potential (MMP) and decreased intracellular ROS in renal proximal tubular cells. by Jun-Feng Chen (494741)

DMB treatment decreased neuronal apoptosis in cerebral ischemia. by Huinan Zhang (849524)

Twenty-one of the most prevalent human autoimmune diseases, in approximately decreasing order of prevalence [49], [275]. by Kenneth Andrew Ross (591738)

liver tissue, stained with H&E, of (a) normal rats showing normal hepatic parenchyma with normal hepatocytes, (b) TAA-treated group showing disrupted hepatic parenchyma, with massi... by Sally A. El Awdan (710176)

Mangiferin Decreases Plasma Free Fatty Acids through Promoting Its Catabolism in Liver by Activation of AMPK by Yucun Niu (186774)

“…Mangiferin (50, 100, 150 mg/kg BW) decreased dose-dependently FFA and triglycerides (TG) levels in plasma, and their accumulations in liver, but increased the β-hydroxybutyrate levels in both plasma and liver of hyperlipidemic rats. …”

Filamentation induced by DTPA is associated with a decrease in Nrg1 protein level, and requires the cAMP-PKA pathway and the kinase Sok1. by Elizabeth J. Polvi (3163500)

a-f. PSP significantly decreased NP-specific IgM responses at days 4 and 21 compared to ACACIA. by Bhagwant Kaur Sekhon (847697)

Anti-CXCR3 group decreased number of specific CD8⁺ T cells as well as polyfunctionality after infection with <i>T</i>. <i>cruzi</i>. by Camila Pontes Ferreira (6194006)

Tg2576 mice treated with OG showed markedly increased α-secretase cleavage of APP and significantly decreased levels of Aβ generation. by She-Qing Zhang (446556)

Stable carbon isotope ratios (a) and nitrogen isotope ratios (b) in 9 cheetahs (8 males, 1 female) in four tissues with decreasing isotopic retention time: fur, muscle, red blood c... by Christian C. Voigt (103380)

Effect of Safr and Cands on the levels of complex I (U/mg protein), complex II (U/mg protein), complex IV (U/mg protein), caspase-3 (Casp-3, μg/mg protein), Fas ligand (FasL, μg/mg... by Nagwa Ibrahim Shehata (17319689)

Subjects:

The effects of TDBP-TAZTO (5 and 50 mg/kg) on spatial learning and memory in rats in the Morris water test. by Liang Ye (6646)

“…Data ate expressed as mean ± SE (n = 10/group). ^a<i>p</i> < 0.05, TDBP-TAZTO 5 mg/kg group vs. control group; ^b<i>p</i> < 0.05, TDBP-TAZTO 50 mg/kg group vs. control group.…”

Temporal profiles of the key BO-NN features. by Julia Berezutskaya (9080269)

“…Right plot show the gradual decrease in the TM tuning for the features highlighted in <b>c</b> as well as the gradual increase in the temporal response profile (i.e. optimal shifts for the prediction of the key BO-NN features using Praat features shown in <b>a</b>). …”

Lovastatin treatment decreases ICAM-1 and CD11b expression and vascular permeability and induce HMOX-1 expression in the brains of mice with CM. by Patricia A. Reis (109310)

Effectiveness of E cytotoxicity presented as a half maximal growth inhibitory concentration (CC₅₀). by Anna Kalota (7415)

Inhibition of G9a decreases the tumorigenicity of neuroblastoma cells. by Xiao-Xue Ke (626989)

The Anion [Mg₆Cl₈Cp*₅]^-:  A Final Intermediate on the Way to the Molecular Donor-Free Grignard Compound MgClCp*? by Jean Vollet (2644651)

“…At a slightly higher temperature and by stepwise decrease of the diethyl ether concentration before reaction, a preferred formation of metal clusters such as dodekakispentamethylcyclopentadienylpentaconta-aluminum, Al₅₀Cp*₁₂, was frequently observed. …”

Soil Carbon Stocks Decrease following Conversion of Secondary Forests to Rubber (<i>Hevea brasiliensis</i>) Plantations by Marleen de Blécourt (435325)

Orsay virus infection of the <i>lin-8(n2731</i>) synMuv A mutant induces a Muv phenotype indicative of decreased synMuv B gene activity, and 2 different synMuv B mutants produce 50–100× less Orsay virus RNA. by Ashwin Seetharaman (615458)

Image_1_Decrease in Serum Urate Level Is Associated With Loss of Visceral Fat in Male Gout Patients.tif by Zijing Ran (11429935)

“…Subjects included had all been treated with urate-lowering therapy (ULT) (febuxostat 20–80 mg/day or benzbromarone 25–50 mg/day, validated by the medical record). …”